Luc Maroteaux

Dr. Luc Maroteaux

orcid

Research Focus & Metrics

Academic Career Length

48Years (1979-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 1988 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
LMLuc Maroteaux
Luc Maroteaux
JCJt Campanelli
Jt Campanelli
RSRh Scheller
Rh Scheller
We used an antiserum against purified cholinergic synaptic vesicles from Torpedo and expression screening to isolate a cDNA clone encoding synuclein, a 143 amino acid neuron-specific protein. A cDNA clone was also isolated from a rat brain cDNA library that encodes a highly homologous 140 amino acid protein. The amino terminal 100 amino acids of both proteins are comprised of an 11 amino acid repeating unit that contains a conserved core of 6 residues. The synuclein gene is expressed only in nervous system tissue, not in electric organ, muscle, liver, spleen, heart, or kidney. In the electric organ synapse Torpedo synuclein-immunoreactive proteins are found in 3 major molecular-weight classes of 17.5, 18.5, and 20.0 kDa. In the neuronal cell soma the 17.5 kDa species is predominant and immunoreactivity is localized to a portion of the nuclear envelope.

1 December 2003 in Nature Reviews Neuroscience
Verified
Journal Article
Closed access
PGPatricia Gaspar
Patricia Gaspar
OCOlivier Cases
Olivier Cases
LMLuc Maroteaux
Luc Maroteaux

16 September 2002 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
JLJ.-M. Launay
J.-M. Launay
PHP. Hervé
P. Hervé
KPKatell Peoc'h
Katell Peoc'h
CTC. Tournois
C. Tournois
JCJ. Callebert
J. Callebert
LMLuc Maroteaux
Luc Maroteaux

15 August 2000 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
CNCanan G. Nebigil
Canan G. Nebigil
DCDoo-Sup Choi
Doo-Sup Choi
ADAndrée Dierich
Andrée Dierich
PHPierre Hickel
Pierre Hickel
MMMarianne Le Meur
Marianne Le Meur
LMLuc Maroteaux
Luc Maroteaux
Several lines of evidence suggest that the serotonin (5-hydroxytryptamine, 5-HT) regulates cardiovascular functions during embryogenesis and adulthood. 5-HT binds to numerous cognate receptors to initiate its biological effects. However, none of the 5-HT receptor disruptions in mice have yet resulted in embryonic defects. Here we show that 5-HT 2B receptor is an important regulator of cardiac development. We found that inactivation of 5-HT 2B gene leads to embryonic and neonatal death caused by heart defects. 5-HT 2B mutant embryos exhibit a lack of trabeculae in the heart and a specific reduction in the expression levels of a tyrosine kinase receptor, ErbB-2, leading to midgestation lethality. These in vivo data suggest that the Gq-coupled receptor 5-HT 2B uses the signaling pathway of tyrosine kinase receptor ErbB-2 for cardiac differentiation. All surviving newborn mice display a severe ventricular hypoplasia caused by impaired proliferative capacity of myocytes. In adult mutant mice, cardiac histopathological changes including myocyte disarray and ventricular dilation were consistently observed. Our results constitute genetic evidence that 5-HT via 5-HT 2B receptor regulates differentiation and proliferation of developing and adult heart. This mutation provides a genetic model for cardiopathy and should facilitate studies of both the pathogenesis and therapy of cardiac disorders in humans.

1 October 1991 in Molecular Brain Research
Verified
Journal Article
Closed access
LMLuc Maroteaux
Luc Maroteaux
RSR.H. Scheller
R.H. Scheller

25 April 2011 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
CDClara Dees
Clara Dees
AAAlfiya Akhmetshina
Alfiya Akhmetshina
PZPawel Zerr
Pawel Zerr
NRNicole Reich
Nicole Reich
KPKatrin Palumbo
Katrin Palumbo
JDJörg H.W. Distler
Jörg H.W. Distler
Vascular damage and platelet activation are associated with tissue remodeling in diseases such as systemic sclerosis, but the molecular mechanisms underlying this association have not been identified. In this study, we show that serotonin (5-hydroxytryptamine [5-HT]) stored in platelets strongly induces extracellular matrix synthesis in interstitial fibroblasts via activation of 5-HT2B receptors (5-HT2B) in a transforming growth factor β (TGF-β)–dependent manner. Dermal fibrosis was reduced in 5-HT2B−/− mice using both inducible and genetic models of fibrosis. Pharmacologic inactivation of 5-HT2B also effectively prevented the onset of experimental fibrosis and ameliorated established fibrosis. Moreover, inhibition of platelet activation prevented fibrosis in different models of skin fibrosis. Consistently, mice deficient for TPH1, the rate-limiting enzyme for 5-HT production outside the central nervous system, showed reduced experimental skin fibrosis. These findings suggest that 5-HT/5-HT2B signaling links vascular damage and platelet activation to tissue remodeling and identify 5-HT2B as a novel therapeutic target to treat fibrotic diseases.